Qilian International Holding Group Limited Signs Agreement with District Government, Settling the Project in Local High-tech Zone
05 Agosto 2021 - 3:30PM
Qilian International Holding Group Limited (Nasdaq: QLI) (the
“Company”), a China-based pharmaceutical and chemical products
manufacturer, today announced that the Company, through its PRC
subsidiary Chengdu Qilianshan Biotechnology Co., Ltd. (“Chengdu
QLS”), entered into an agreement (the “Agreement”) with Chongqing
Tongnan District Government (“CTDG”). Pursuant to the Agreement,
the Company’s new pig by-product processing facility (the
“Project”) will be located in Tongnan High-tech Zone. CTDG agrees
to provide the Company with preferential policies and support
funds.
The Company chose to locate the Project in
Tongnan High-tech Zone as it plans to increase its R&D efforts
to boost the production of heparin sodium preparations. The Company
expects to generate additional income from this Project.
Since 2020, the Company's heparin sodium
industrialization development plan has received high attention from
local and neighboring local governments. In March 2021, the Project
was listed as one of key investment projects by Chongqing Tongnan
High-Tech Zone. In June, the management of the Company was invited
to Suining, Tongnan - Sichuan Chengdu Adjacent Areas of Integrated
Development of Global Investment Promotion Conference, which was
co-sponsored by Sichuan Provincial People's Government and
Chongqing Municipal People's Government, during which the Company
reached a preliminary agreement with CTDG for future
cooperation.
Located in Chengdu, Sichuan Province, Chengdu
QLS has been producing Heparin Sodium Preparations and Zhu
Xiaochang® sausage casings since 2015, relying on the advantages of
the extremely rich pig breeding resources in Sichuan and Chongqing.
In recent years, with increasing research and development
capability, maturing production technology and expanding production
and sales volume, Chengdu QLS have expanded the market share of its
heparin sodium products and become a growing driver of the
Company’s business operations.
The Company’s core product Heparin Sodium
Preparations is one kind of Heparin, which widely used for
anticoagulant and antithrombotic purposes globally. Cardiovascular
and cerebrovascular diseases have become some of the leading causes
of death globally. Heparin is considered to have a good performance
in the treatment of more than 40 diseases in 12 clinical
disciplines such as hematological disorders, heart disease,
extracorporeal circulation surgery, and blood purification therapy.
The market size of anticoagulants around the globe is growing
rapidly with huge potential. According to Global Anticoagulant
Drugs Market Size, Manufacturers, Supply Chain, Sales Channel and
Clients, 2021-2027 published by ReportsnReports, the market size of
anticoagulants around the globe in 2020 was US$28,690 million and
it is expected to reach US$38,850 million by the end of 2027, with
a compound annual growth rate of 4.8% from 2021 to 2027.
Mr. Zhanchang Xin, Chairman and CEO of the
Company, commented, “The landing of the Project is an important
step in the strategic layout of the Company's industrial
development. The Company will focus on the Project with its
research and development results and understanding of the industry,
scale up its production, and lay a solid foundation for entering
into the market of low-molecular heparin raw materials, which has
higher added value and development potential.”
About Qilian International Holding Group
Limited
Qilian International Holding Group Limited,
headquartered in Gansu, China, is a pharmaceutical and chemical
products manufacturer in China. It focuses on the development,
manufacture, marketing and sale of licorice products,
oxytetracycline products, traditional Chinese medicine derivatives
product, heparin product, sausage casings, and fertilizers. The
Company’s products are sold in more than 20 provinces in China. For
more information, visit the company’s website
at http://ir.qlsyy.net/.
Forward-Looking Statements
This announcement contains forward-looking
statements within the meaning of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. All statements
other than statements of historical fact in this announcement
are forward-looking statements. These forward-looking statements
involve known and unknown risks and uncertainties and are based on
current expectations and projections about future events and
financial trends that the Company believes may affect its financial
condition, results of operations, business strategy, financial
needs and the successful construction of the pig by-product
processing project facility. Investors can identify these
forward-looking statements by words or phrases such as "may,"
"will," "expect," "anticipate," "aim," "estimate," "intend,"
"plan," "believe," "potential," "continue," "is/are likely to" or
other similar expressions. The Company undertakes no obligation to
update forward-looking statements to reflect subsequent occurring
events or circumstances, or changes in its expectations, except as
may be required by law. Although the Company believes that the
expectations expressed in these forward-looking statements are
reasonable, it cannot assure you that such expectations will turn
out to be correct, and the Company cautions investors that actual
results may differ materially from the anticipated results and
encourages investors to review other factors that may affect
its future results in the Company’s registration statement and
in its other filings with the SEC.
For more information, please
contact:
Qilian International Holding Group Limited
Email: ir@qlsyy.net
Ascent Investors Relations LLC
Tina Xiao
President
Phone: 917-609-0333
Email: tina.xiao@ascent-ir.com
Qilian (NASDAQ:QLI)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Qilian (NASDAQ:QLI)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024